Autopsy report · NCT04618393

A Study of EMB-02 in Participants With Advanced Solid Tumors

“Company's resource optimization and product's development change”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 3 years before it stopped.
• 47 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd.

Sponsor type

Industry

Conditions

Advanced Solid Tumors

Interventions

EMB-02

Participants

47

Sites

10

Countries

Australia, China, United States

Trials that died the same way

• A Clinical Investigation to Assess the Effectiveness of Benzocaine Condoms in Healthy Adult Men
  “Change of the product development strategy” (76% match in meaning)
• Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
  “Company development strategy change” (72% match in meaning)
• IBI397 or Combination Therapies in Patients With Advanced Malignancies
  “Due to the company's development strategy adjustment” (68% match in meaning)
• Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors
  “Company Development strategy adjustment” (68% match in meaning)
• Evaluate the Efficacy and Safety of Amnion Membrane Disc Allograft vs Standard of Care in Participants With Dry Eye Disease
  “Change in company strategy.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.